Table 1.
Contributions of age, sex, and tumor stage to tumor exonic missense mutational burden (TEMMB). Each model was additionally adjusted by recruitment center (IRR and p-values not shown).
| Age | Sex | Tumor Stage | ||||||
|---|---|---|---|---|---|---|---|---|
| Age, yrs (IRRa) | p b | Fem (ref) | Male (IRRa) | p b | I-II (ref) | III + (IRRa) | p b | |
| ACC | 1.02 [1.01–1.03] | <0.05/31** | 1 | 0.78 [0.57–1.09] | 0.14 | 1 | 1.35 [0.99–1.85] | 0.06 |
| BLCA | 1.00 [0.99–1.02] | 0.56 | 1 | 1.30 [0.95–1.76] | 0.08 | 1 | 1.37 [1.03–1.80] | <0.05* |
| BRCA | 1.01 [1.01–1.02] | <0.05/31** | 1 | 0.64 [0.35–1.33] | 0.19 | 1 | 0.78 [0.67–0.91] | <0.05/24** |
| CESC | 1.02 [1.01–1.03] | <0.05/31** | 1 | — | — | 1 | 1.09 [0.76–1.61] | 0.63 |
| CHOL | 1.01 [1.00–1.01] | 0.07 | 1 | 0.93 [0.80–1.08] | 0.32 | 1 | 0.81 [0.68–0.97] | <0.05* |
| COAD | 1.00 [0.98–1.01] | 0.76 | 1 | 0.57 [0.39–0.83] | <0.05* | 1 | 0.50 [0.34–0.74] | <0.05/24** |
| DLBC | 1.00 [0.99–1.02] | 0.70 | 1 | 1.26 [0.80–1.97] | 0.31 | 1 | 0.57 [0.33–1.01] | <0.05* |
| ESCA | 1.01 [1.00–1.02] | <0.05* | 1 | 0.89 [0.71–1.11] | 0.32 | 1 | 0.99 [0.83–1.19] | 0.95 |
| GBM | 1.01 [1.00–1.01] | <0.05/31** | 1 | 0.87 [0.80–0.94] | <0.05/26** | 1 | — | — |
| HNSC | 1.01 [1.01–1.02] | <0.05/31** | 1 | 1.04 [0.85–1.27] | 0.69 | 1 | 1.00 [0.80–1.23] | 0.98 |
| KICH | 1.00 [1.00–1.01] | 0.09 | 1 | 0.93 [0.79–1.09] | 0.37 | 1 | 1.25 [1.06–1.47] | <0.05* |
| KIRC | 1.01 [1.01–1.02] | <0.05/31** | 1 | 1.04 [0.91–1.18] | 0.57 | 1 | 1.01 [0.89–1.16] | 0.87 |
| KIRP | 1.01 [1.01–1.02] | <0.05/31** | 1 | 1.20 [1.07–1.34] | <0.05/26** | 1 | 1.11 [1.00–1.25] | 0.06 |
| LAML | 1.01 [1.00–1.02] | <0.05/31** | 1 | 1.11 [0.91–1.36] | 0.30 | 1 | — | — |
| LGG | 1.02 [1.02–1.03] | <0.05/31** | 1 | 0.94 [0.85–1.04] | 0.21 | 1 | — | — |
| LIHC | 1.00 [1.00–1.01] | 0.24 | 1 | 1.06 [0.86–1.29] | 0.58 | 1 | 0.94 [0.76–1.17] | 0.59 |
| LUAD | 1.00 [0.99–1.01] | 0.99 | 1 | 1.18 [0.92–1.50] | 0.19 | 1 | 0.81 [0.62–1.07] | 0.13 |
| LUSC | 0.99 [0.98–1.01] | 0.35 | 1 | 1.04 [0.83–1.28] | 0.75 | 1 | 1.01 [0.80–1.29] | 0.91 |
| OV | 1.01 [1.00–1.01] | <0.05/31** | 1 | — | — | 1 | 0.67 [0.50–0.89] | <0.05* |
| PAAD | 1.00 [0.99–1.01] | 0.92 | 1 | 1.11 [0.97–1.27] | 0.14 | 1 | 1.11 [0.82–1.53] | 0.51 |
| PCPG | 1.01 [1.01–1.02] | <0.05/31** | 1 | 1.06 [0.93–1.22] | 0.38 | 1 | — | — |
| PRAD | 1.00 [0.99–1.01] | 0.84 | 1 | — | — | 1 | — | — |
| READ | 0.98 [0.96–1.00] | 0.05 | 1 | 0.92 [0.61–1.38] | 0.68 | 1 | 0.56 [0.37–0.85] | <0.05* |
| SARC | 1.02 [1.01–1.03] | <0.05/31** | 1 | 1.43 [1.17–1.75] | <0.05/26** | 1 | — | — |
| SKCM | 1.01 [1.00–1.02] | <0.05* | 1 | 1.39 [1.11–1.72] | <0.05* | 1 | 0.93 [0.74–1.17] | 0.51 |
| STAD | 1.02 [1.00–1.03] | <0.05* | 1 | 0.95 [0.68–1.32] | 0.72 | 1 | 0.95 [0.69–1.30] | 0.72 |
| THCA | 1.01 [1.01–1.02] | <0.05/31** | 1 | 0.96 [0.85–1.08] | 0.49 | 1 | 1.14 [1.00–1.30] | <0.05* |
| THYM | 1.03 [1.02–1.05] | <0.05/31** | 1 | 1.19 [0.85–1.66] | 0.31 | 1 | — | — |
| UCEC | 0.98 [0.96–0.99] | 0.14 | 1 | — | — | 1 | 0.79 [0.47–1.37] | 0.31 |
| UCS | 1.00 [0.98–1.02] | 0.89 | 1 | — | — | 1 | 1.20 [0.88–1.63] | 0.21 |
| UVM | 1.00 [1.00–1.01] | 0.43 | 1 | 1.13 [0.96–1.34] | 0.14 | 1 | 0.81 [0.67–0.98] | <0.05** |
Older age correlated with high TEMMB in 17 of 31 cancers studied. Effects of male sex and high tumor stage (defined as Stage III or greater) were variable.
aIRR: Incidence rate ratio calculated with multivariate binomial regression, reported with 95% confidence intervals.
bp-values displayed with conventional 0.05 significance cutoff and with cutoff using Bonferroni correction for multiple comparisons (n = 31, 26, 24 for age, sex, stage respectively).